TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03879772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Description: intranasal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Description: intranasal administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo nasal spray
Description: intranasal administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray
Description: intranasal administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorpheniramine maleate syrup
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate syrup
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate syrup
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate syrup
Description: oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chlorpheniramine maleate syrup
Description: oral administration
Study: NCT02254070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBT 986 BS
Study: NCT00912808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: donepezil, 5 mg, capsule, once a day, 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill (placebo)
Description: sugar pill, one capsule, once a day, 3 weeks
Study: NCT00157131

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin Sealant, ARTISS 4IU/ml VH SD
Description: FS 4IU VH S/D, a two-component fibrin sealant with 4 IU/mL human thrombin, vapor heated, solvent detergent treated, provided in a frozen, ready-to-use formulation. Administration by a topical spray application using the TISSOMAT device and Spray Set.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Staples
Description: Administration by mechanical/multiple point fixation.
Study: NCT00598338

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prucalopride
Description: 4 mg o.d.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: o.d.
Study: NCT05104138

Intervention type: DRUG
Intervention: Eplerenone
Description: The patients underwent eplerenone treatment for 6 months

Intervention type: DEVICE
Intervention: The patients underwent half fluence photodynamic therapy for 6 months
Description: Half fluence photodynamic therapy for 6 months
Study: NCT03817216

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prostatic Urethral Lift (PUL)
Description: PUL/ UroLift® is an FDA-approved device for the treatment of obstructive symptoms due to benign prostatic hyperplasia (BPH). This study evaluates UroLift's efficacy participants with obstructive symptoms who are candidates for radiotherapy or those who developed obstructive symptoms after radiotherapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostatic Urethral Lift (PUL)
Description: PUL/ UroLift® is an FDA-approved device for the treatment of obstructive symptoms due to benign prostatic hyperplasia (BPH). This study evaluates UroLift's efficacy participants with obstructive symptoms who are candidates for radiotherapy or those who developed obstructive symptoms after radiotherapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostatic Urethral Lift (PUL)
Description: PUL/ UroLift® is an FDA-approved device for the treatment of obstructive symptoms due to benign prostatic hyperplasia (BPH). This study evaluates UroLift's efficacy participants with obstructive symptoms who are candidates for radiotherapy or those who developed obstructive symptoms after radiotherapy.
Study: NCT01502826

Intervention type: DIETARY_SUPPLEMENT
Intervention: standardized mixed meal
Description: All participants will undergo a mixed meal test (300 kcal/m2 of body surface area, 53.8% carbohydrates, 29.5% lipids, 16.7% proteins) and will be monitored for 300 minutes thereafter.

Intervention type: DIETARY_SUPPLEMENT
Intervention: standardized mixed meal
Description: All participants will undergo a mixed meal test (300 kcal/m2 of body surface area, 53.8% carbohydrates, 29.5% lipids, 16.7% proteins) and will be monitored for 300 minutes thereafter.
Study: NCT06522646

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPCM
Description: During a period of 4-6 weeks, patients will live in their usual environment with the SPCM prosthesis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Prothesis
Description: During a period of 4-6 weeks, patients will live in their usual environment with their usual microprocessor prosthesis
Study: NCT02878031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin for CI pneumonia
Description: CHW management of chest indrawing (CI) pneumonia in children 2-59 months old using oral amoxicillin, given in the following age specific dosage:~2 months ≤ children age \<12 months (4 - \<10kg): one (1) tablet 250mg dispersible amoxicillin twice daily (morning and evening) for 5 days.~12 months≥ children age \<3 years (10 kg - \<14 kg): two (2) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days.~≥ 3 years of age children \<5 years (14kg - 19kg): three (3) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days.
Study: NCT02396576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Intervention
Description: The telehealth model will integrate developmental, behavioral, (DB) and mental health services (MH) into pediatric primary care using videoconferencing that will be tested with children in low-income, urban communities.
Study: NCT01961037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tai Chi: Moving for Better Balance
Description: Participants will attend one-hour Tai Chi classes twice weekly for 16 weeks.
Study: NCT02322632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol Capsules, 4 mcg
Description: Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol Capsules, 4 mcg
Description: Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
Study: NCT01995838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2006
Description: E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
Study: NCT03415685

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PicoPlus laser system
Description: Laser treatment using specific pulse durations and wavelengths for selective pigment photothermolysis.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PicoPlus laser system
Description: Laser treatment using specific pulse durations and wavelengths for selective pigment photothermolysis.
Study: NCT03836313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iovera°
Description: Cryoneurolysis treatment using the iovera° device targeting the anterior femoral cutaneous nerve (AFCN) and the infrapatellar branch of the saphenous nerve (ISN) will occur approximately 4 weeks before surgery by a trained member of the study staff. Treatment will occur in clinic using suggested anatomical markings to target appropriate the AFCN and infrapatellar branch of the saphenous nerve (ISN) of the operative knee.~The iovera° device contains three 27- gauge needles, all 6.9mm in length which will indent the subjects' skin and be inserted under the subcutaneous fat about 7 mm. Lidocaine will be used for superficial anesthetic at the treatment site before the needles puncture the patient's skin.There are a total of 9 iovera° cooling cycles. Treatment will be performed unilaterally and will be guided by visualization and palpation of anatomical landmarks.
Study: NCT02512783

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous administration of propofol according to standard care to sedate patient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Intravenous administration of propofol according to standard care to sedate patient.
Study: NCT04532528

Intervention type: DRUG
Intervention: Dabigatran
Description: Dabigatran

Intervention type: DRUG
Intervention: Dabigatran
Description: Dabigatran
Study: NCT01023763

Intervention type: OTHER
Group type: OTHER
Intervention: A structured training program
Description: A structured training program in nursing homes in the intravenous treatment of dehydration and infections.
Study: NCT00212108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib, gefitinib
Description: The dose of ZD1839 to be administered is 250mg. ZD1839 will be taken once daily in the morning at approximately the same time each day. If the patient inadvertently did not take the dose in the morning, the patient may take that dose anytime up to 10pm that same day. The daily treatment will be resumed the next day at the scheduled morning dose. Celecoxib will be administered at 400 mg bd.
Study: NCT03987269

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Embodied Virtual Reality
Description: The video will be formatted for viewing within a standard virtual reality headset. Once the video begins, subjects will follow the movements of the new body they are inhabiting in synchronicity to the video. Movement and haptic input include~1. Mimicking the hand gestures at the beginning in order to establish the body transfer illusion.~2. Shaking someone's hand~3. Someone holding the hand and elbow to assist them in standing, taking a few steps and returning to a seated position.~4. Shaking hands~5. Having their blood pressure taken~6. Having their pulse taken~7. Fill a pill organizer~8. Color a picture~All of the above interactions will be facilitated by the two Co-PI's (Blatter, Ware). Blatter and Ware have been creating and performing similar Virtual Reality Embodiments with haptics for the past year, and to date, have performed hundreds of them for demos, colleagues, students and the public.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Narrative Video
Description: The video will be formatted for a standard flat screen television. Participants will watch the video alone in a standard School of the Arts classroom.
Study: NCT03725397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outpatient
Description: The offered (studied) intervention will be allowing the women with a transcervical Foley catheter in place to spend the night at home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient
Description: Women with a transcervical Foley catheter to be admitted to the hospital overnight which has been a standard of care.
Study: NCT01152632

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: manual acupuncture
Description: thirty minutes duration every time, five times per week for one course, a total four courses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual acupuncture
Description: thirty minutes duration every time, five times per week for one course, a total four courses
Study: NCT03518853

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course Hypofractionated Once-weekly Radiation Therapy
Description: Eligible patients will be treated with a radiation regimen of 35 Gy in 5 fractions delivered at one fraction per week at 7 day intervals. The dose of radiotherapy is based on the consensus alpha beta ratio of 1.5.
Study: NCT02940795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coke
Description: Patients were given a 20 ounce bottle of Coke Cola.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coke
Description: Patients were given a 20 ounce bottle of Coke Cola.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Rite
Description: Patients were given a 12 ounce can of Diet Rite.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Rite
Description: Patients were given a 12 ounce can of Diet Rite.
Study: NCT00517387

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine XR
Description: All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
Study: NCT04218526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vercise DBS System
Description: Vercise Deep Brain Stimulation (DBS) System that consists of two bilateral directional DBS Cartesia electrodes implanted in the cuneiform nucleus and a Gevia generator implanted in the upper chest area just below the clavicle.
Study: NCT02870595

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Microvibratory Stimulator
Description: Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microvibratory Stimulator
Description: Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Microvibratory Stimulator'
Description: As above, Microvibratory Stimulator will be used as a sham device in parallel group.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Microvibratory Stimulator'
Description: As above, Microvibratory Stimulator will be used as a sham device in parallel group.
Study: NCT04170608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FARAPULSE Endocardial Multi Ablation System
Description: Ablation using the FARAPULSE Endocardial Multi Ablation System
Study: NCT02080715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: 2 x 100mg Tolcapone compared to placebo (randomized, double-blind, cross-over)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT01161277

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Dose: 5-10 mg depending on subject weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Dose: 1-2 mg depending on subject weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sugar pill
Description: Dose: 1-2 pills depending on subject weight
Study: NCT02633098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate 200mg
Description: Artesunate 200mg PO OD for 14 days prior to colorectal resection surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo PO OD for 14 days prior to colorectal resection surgery
Study: NCT04565132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Definition transcranial Direct Current Stimulation
Description: 1x1 tDCS low-intensity stimulator and 4x1 multichannel stimulation adaptor (Soterix Medical Inc, New York, NY)
Study: NCT03631251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Placebo
Description: Open placebo in addition to the standard course of opioids. Opioids are given consistent with standard care.
Study: NCT02307825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: The drug will be taken three times a week for four months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be taken three times a week for four months.
Study: NCT02383576

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention administered in this study.

Intervention type: OTHER
Intervention: No Intervention
Description: No intervention administered in this study.
Study: NCT04502095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diary
Description: Complete drug diary

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim-Sulfamethoxazole
Description: Given PO
Study: NCT01152632

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: manual acupuncture
Description: thirty minutes duration every time, five times per week for one course, a total four courses

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manual acupuncture
Description: thirty minutes duration every time, five times per week for one course, a total four courses
Study: NCT01630746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-438
Study: NCT04147078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine subcutaneous administration
Description: subcutaneous administration
Study: NCT01182701

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral training
Description: The behavioral training group will be involved six group sessions focusing on cognitive behavioral training for stress and mood management, cognitive restructuring, empowerment, values clarification, problem solving and decision making via a manualized program
Study: NCT02561754

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Enhanced Stop Light Diet (eSLD)
Description: eSDL includes reduced energy portion controlled meals for 6 months, encouraged consumption of lower energy shakes and 35 fruits and vegetables per week.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Diet (CD)
Description: CD is a nutritionally balanced, reduced energy, high volume, lower fat ( fat=20-30% energy) diet.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conventional Diet (CD)
Description: CD is a nutritionally balanced, reduced energy, high volume, lower fat ( fat=20-30% energy) diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face (FTF)
Description: FTF will meet with a health educator in person and will track progress using pen and paper records for both physical activity and diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology (TECH)
Description: TECH groups will receive the intervention using an iPad with the FaceTimeTM application for video meetings with a health educator and will track progress using the Lose it! application for both physical activity and diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology (TECH)
Description: TECH groups will receive the intervention using an iPad with the FaceTimeTM application for video meetings with a health educator and will track progress using the Lose it! application for both physical activity and diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad with FaceTime
Description: TECH groups will receive the intervention using an iPad with the FaceTimeTM to the intervention field.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iPad with FaceTime
Description: TECH groups will receive the intervention using an iPad with the FaceTimeTM to the intervention field.
Study: NCT00408239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM150
Description: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: Sub cutaneous
Study: NCT03507465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole Plus Low-Dose Metronomic Capecitabine
Description: Letrozole Plus Low-Dose Metronomic Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC-T
Description: Epirubicin/Cyclophosphamide Followed by Docetaxel
Study: NCT03834051

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation Rectal Administration Open Label
Study: NCT04717037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Olive Oil Massage
Description: olive oil massage application.
Study: NCT03777982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Taking advantage of the anti-inflammatory properties of the medication, corticosteroids are used to decrease the swelling around tumors.
Study: NCT00821574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Description: Fluvastatin: daily 80 mg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Valsartan: daily 160 mg, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide: daily 12.5mg, oral